Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Champions Oncology, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +2 vs. Q4 2023
- Shares held
- 5.63M
- +21.3K (+0.4%) vs. Q4 2023
- Total value
- $27.6M
- −$3.88M (−12.3%) vs. Q4 2023
- New holders
- 5
- 6 more added
- Sold out
- 3
- 9 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CSBR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 28 | $36.3M |
| Q1 2026 | 25 | $33.0M |
| Q4 2025 | 27 | $39.7M |
| Q3 2025 | 27 | $36.7M |
| Q2 2025 | 30 | $42.5M |
| Q1 2025 | 34 | $51.4M |
| Q4 2024 | 25 | $49.0M |
| Q3 2024 | 22 | $28.2M |
| Q2 2024 | 23 | $29.9M |
| Q1 2024 | 25 | $27.6M |
| Q4 2023 | 23 | $31.5M |
| Q3 2023 | 29 | $35.6M |
| Q2 2023 | 28 | $37.0M |
| Q1 2023 | 30 | $23.6M |
| Q4 2022 | 29 | $27.1M |
| Q3 2022 | 32 | $46.8M |
| Q2 2022 | 32 | $49.8M |
| Q1 2022 | 30 | $50.4M |
| Q4 2021 | 31 | $51.7M |
| Q3 2021 | 35 | $64.1M |
| Q2 2021 | 38 | $68.5M |
| Q1 2021 | 45 | $81.4M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Champions Oncology, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 64 | $0 | 0.00% | −156−70.9% | Reduced |
| JPMorgan Chase & Co | 11 | $54 | 0.00% | −89−89.0% | Reduced |
| Wells Fargo & Company | 47 | $230 | 0.00% | +1+2.2% | Added |
| UBS Group AG | 1,107 | $5.42K | 0.00% | −1,122−50.3% | Reduced |
| Simplex Trading, LLC | 1,597 | $7.00K | 0.00% | +1,597 | New |
| Stifel Financial Corp | 11,192 | $54.8K | 0.00% | +11,192 | New |
| Cambridge Investment Research Advisors, Inc. | 12,252 | $60.0K | 0.00% | +12,252 | New |
| Mesirow Financial Investment Management, Inc. | 12,380 | $60.7K | 0.00% | +12,380 | New |
| Citadel Advisors LLC | 12,825 | $62.8K | 0.00% | −1,802−12.3% | Reduced |
| Bank of America Corp | 25,826 | $126.5K | 0.00% | −40.0% | Reduced |
| State Street Corp | 26,553 | $130.1K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 26,749 | $131.1K | 0.00% | −4,026−13.1% | Reduced |
| Acadian Asset Management LLC | 30,697 | $148.0K | 0.00% | 00.0% | Unchanged |
| HighTower Advisors, LLC | 34,308 | $168.0K | 0.00% | +3,070+9.8% | Added |
| Morgan Stanley | 40,700 | $199.4K | 0.00% | +31,600+347.3% | Added |
| Northern Trust Corp | 42,689 | $209.2K | 0.00% | −2,228−5.0% | Reduced |
| Geode Capital Management, LLC | 62,114 | $304.4K | 0.00% | +765+1.2% | Added |
| Goldman Sachs Group Inc | 69,301 | $339.6K | 0.00% | +69,301 | New |
| Essex Investment Management Co LLC | 77,200 | $378.3K | 0.07% | 00.0% | Unchanged |
| Vanguard Group Inc | 85,604 | $419.5K | 0.00% | +2,767+3.3% | Added |
| BlackRock Inc. | 115,683 | $566.8K | 0.00% | −414−0.4% | Reduced |
| Renaissance Technologies LLC | 124,691 | $611.0K | 0.00% | −100−0.1% | Reduced |
| Tocqueville Asset Management L.P. | 684,628 | $3.35M | 0.05% | +500.0% | Added |
| NEA Management Company, LLC | 1,713,720 | $8.40M | 0.52% | 00.0% | Unchanged |
| Battery Management Corp. | 2,421,673 | $11.9M | 2.62% | 00.0% | Unchanged |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −75,044−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −26,839−100.0% | Sold out |
| Aristides Capital LLC | 0 | $0 | 0.00% | −11,822−100.0% | Sold out |